ClinicalTrials.gg
CompletedNCT01531933DIPPER-DMUpdated Aug 7, 2012

Efficacy and Safety of DLBS3233 in Prediabetic Patients

A Phase 3 interventional study of DLBS3233 and Placebo of DLBS3233 in Prediabetic, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2012-08-07.

Sponsored by Dexa Medica Group · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.

Enrollment
27th of 52
80 · median 85
Started
2011
with 1 other
Phase 3
9 of 66
1 open now
Registered
18th of 66
by date
Lead sponsor
5 of 66
Dexa Medica Group

Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 27th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, or all of them as a file.
02

Study summary

This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of DLBS3233.

It is hypothesized that DLBS3233 will delay the progress of beta-cell dysfunction as measured by the improvement of prandial (particularly the first phase) insulin secretion as well as insulin resistance in prediabetic subjects which may prevent the conversion of prediabetes into type 2 diabetes mellitus.

Read the detailed description

There will be two groups of treatment in this study who will receive DLBS3233 or placebo of DLBS3233 for 12 weeks of therapy.

Subjects will be provided with an education on lifestyle modification given by the assigned nutritionist. All subjects will be advised to follow such a lifestyle modification throughout the study period.

All subjects will be under direct supervision of a medical doctor during the study period.

All clinical and laboratory examinations to evaluate the investigational drug's efficacy, will be performed at baseline, Week 8th and Week 12th (end) of study treatment. Blood glucose level (both FPG and 2h-PG) will be performed at baseline and at interval of 4 weeks over the 12 weeks of study treatment. Safety examinations will be performed at baseline and at the end of study. Occurrence of adverse event will be observed during the study.

03

Conditions studied

  • Prediabetic

Keywords

  • Prediabetic
  • Primary prevention
  • Type 2 diabetes mellitus
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with age of 18-60 years
  • Prediabetic patients (2h-PPPG level of 140-199 mg/dL)
  • Serum ≤ 2.5 times
  • Serum creatinine \< 1.5 times upper limit of normal
  • Able to take oral medication

Exclusion criteria

Exclusion Criteria:

  • Female of
  • History of diabetes mellitus
  • History of symptomatic coronary arterial disease, stroke, and cardiovascular events
  • Current treatment with systemic or herbal (alternative) medicines
  • Any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation
  • Participation in any other clinical studies within 30 days prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    DLBS3233

    Drug: DLBS3233

  • Placebo comparator
    Placebo of DLBS3233

    Drug: Placebo of DLBS3233

Interventions

  • For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.

    Also known as: Inlacin

  • DrugPlacebo of DLBS3233

    For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.

06

What researchers measure

Primary outcomes

  1. Change in 15-minute post prandial insulin level

    Change in 15-minute post prandial insulin level from baseline to 12 weeks of treatment

    Time frame: 12 weeks of treatment

Secondary outcomes

  1. Change in 15-minute post prandial insulin level

    Change in 15-minute post prandial insulin level from baseline to 8 weeks of treatment

    Time frame: 8 weeks of treatment

  2. Change in 2-hour post prandial insulin level

    Change in 2-hour post prandial insulin level from baseline to 8 weeks and to 12 weeks of treatment

    Time frame: 8 weeks and 12 weeks of treatment

  3. Change in 15-minute post prandial plasma glucose

    Change in 15-minute post prandial plasma glucose from baseline to 8 weeks and to 12 weeks of treatment

    Time frame: 8 weeks and 12 weeks of treatment

  4. Change in 2-hour post prandial plasma glucose

    Change in 2-hour post prandial plasma glucose from baseline to each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)

    Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment

  5. Change in HOMA-IR

    Change in HOMA-IR from baseline to 8 weeks and to 12 weeks of treatment

    Time frame: 8 weeks and 12 weeks of treatment

  6. Change in hs-CRP

    Change in hs-CRP from baseline to 8 weeks and to 12 weeks of treatment

    Time frame: 8 weeks and 12 weeks of treatment

  7. Improvement in lipid profile

    Improvement in lipid profile from baseline to 8 weeks and to 12 weeks of treatment, including: fasting plasma HDL-cholesterol, fasting plasma triglyceride, 15-minute post prandial plasma triglyceride, and 2-hour post prandial plasma triglyceride

    Time frame: 8 weeks and 12 weeks of treatment

  8. Change in adiponectin

    Change in adiponectin from baseline to 8 weeks and to 12 weeks of treatment

    Time frame: 8 weeks and 12 weeks of treatment

  9. Change in waist-to-hip ratio

    Change in waist-to-hip ratio from baseline to each of study visit (4 weeks, 8 weeks, and 12 weeks of treatment)

    Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment

  10. ECG

    ECG will be evaluated at baseline and at end of study (12 weeks of treatment)

    Time frame: 12 weeks of treatment

  11. Vital signs

    Vital signs (systolic and diastolic blood pressure, heart rate, respiration rate) will be evaluated at baseline and at each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)

    Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment

  12. Body weight

    Body weight will be evaluated at baseline and at each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)

    Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment

  13. Liver function

    Liver function (levels of serum ALT, γ-GT, alkaline phosphatase) will be evaluated at baseline and at end of study (12 weeks of treatment)

    Time frame: 12 weeks of treatment

  14. Renal function

    Renal function (serum creatinine level) will be evaluated at baseline and at end of study (12 weeks of treatment)

    Time frame: 12 weeks of treatment

  15. Adverse events

    Adverse events as well as number of subjects experienced the events will be observed and evaluated during study period (12 weeks) and until all adverse events have been recovered or stabilized

    Time frame: 1-12 weeks of treatment

07

Study locations

1 site
  • Department of Internal Medicine, dr. M. Djamil Padang Hospital
    Padang, West Sumatera, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2012
First posted
Feb 13, 2012
Start
Nov 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Last update
Aug 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01531933
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Feb 13, 2012
Start date
Nov 2011
Primary completion
Jul 2012
Completion
Jul 2012
Last update
Aug 7, 2012

Study contacts

Asman Manaf, Prof., Dr., dr., SpPD-KEMD
principal investigator · Department of Internal Medicine, dr. M. Djamil Padang Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DLBS3233

Start the discussion